CoChat
Sign Up
Cited by 110

The DOI matches its Crossref record.

Angiotensin 1–9 and 1–7 release in human heart role of cathepsin, A

Jackman, Herbert L., Massad, Malek G., Sekosan, Marin, Tan, Fulong, Brovkovych, Viktor, Marcic, Branislav M., Erdös, Ervin G.·2002·Hypertension
DOI 10.1161/01.hyp.0000017283.67962.02
Open this paper in CoChat — free account

Abstract

Human heart tissue enzymes cleave angiotensin (Ang) I to release Ang 1-9, Ang II, or Ang 1-7. In atrial homogenate preparations, cathepsin A (deamidase) is responsible for 65% of the liberated Ang 1-9. Ang 1-7 was released (88% to 100%) by a metallopeptidase, as established with peptidase inhibitors. Ang II was liberated to about equal degrees by ACE and chymase-type enzymes. Cathepsin A’s presence in heart tissue was also proven because it deamidated enkephalinamide substrate by immunoprecipitation of cathepsin A with antiserum to human recombinant enzyme and by immunohistochemistry. In immunohistochemistry, cathepsin A was detected in myocytes of atrial tissue. The products of Ang I cleavage, Ang 1-9 and Ang 1-7, potentiated the effect of an ACE-resistant bradykinin analog and enhanced kinin effect on the B 2 receptor in Chinese hamster ovary cells transfected to express human ACE and B 2 (CHO/AB), and in human pulmonary arterial endothelial cells. Ang 1-9 and 1-7 augmented arachidonic acid and nitric oxide (NO) release by kinin. Direct assay of NO liberation by bradykinin from endothelial cells was potentiated at 10 nmol/L concentration, 2.4-fold (Ang 1-9) and 2.1-fold (Ang 1-7); in higher concentrations, Ang 1-9 was significantly more active than Ang 1-7. Both peptides had traces of activity in the absence of bradykinin. Ang 1-9 and Ang 1-7 potentiated bradykinin action on the B 2 receptor by raising arachidonic acid and NO release at much lower concentrations than their 50% inhibition concentrations (IC 50 s) with ACE. They probably induce conformational changes in the ACE/B 2 receptor complex via interaction with ACE.

Overview

Integrity signals

Registry

Crossref · 10.1161/01.hyp.0000017283.67962.02

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 49

  1. 10.1161/circ.58.5.699246 · DOI
  2. 10.1016/S0140-6736(00)02212-1 · DOI
  3. Lewis EJ. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy.In: Koide H Ichikawa I eds. Progression of Chronic Renal Diseases.(Contributions to Nephrology Vol. 118). Basel: Karger; 1996: 206–213. · DOI
  4. Yang HY, Erdös EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II; angiotensin I converting enzyme). J Pharmacol Exp Ther. 1971; 177: 291–300.
  5. 10.1161/res.81.5.848 · DOI
  6. 10.1016/S1043-2760(99)00156-3 · DOI
  7. 10.1074/jbc.M909490199 · DOI
  8. Marcic BM, Erdös EG. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther. 2000; 294: 605–612.
  9. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992; 44: 1–80.
  10. Erdös EG Skidgel RA. Metabolism of bradykinin by peptidases in health and disease.In: Farmer SG ed. The Kinin System. London: Academic Press; 1997: 111–141. · DOI
  11. 10.1021/bi00282a035 · DOI
  12. 10.1016/0024-3205(93)90108-F · DOI
  13. 10.1016/S0167-0115(00)00138-5 · DOI
  14. 10.1016/S0167-0115(98)00134-7 · DOI
  15. 10.1161/hyp.31.4.912 · DOI
  16. 10.1172/JCI114061 · DOI
  17. 10.1161/01.RES.87.1.1 · DOI
  18. 10.1074/jbc.M002615200 · DOI
  19. 10.1016/S0021-9258(19)38586-2 · DOI · Paper page
  20. 10.1016/S0021-9258(19)50665-2 · DOI · Paper page
  21. 10.1016/S0021-9258(17)39531-5 · DOI
  22. 10.1074/jbc.270.44.26441 · DOI · Paper page
  23. 10.1021/bi00008a005 · DOI · Paper page
  24. Pshezhetsky AV. Lysosomal carboxypeptidase A.In: Barrett AJ ed. Handbook of Proteolytic Enzymes. London: Academic Press; 1998.
  25. 10.1016/0167-4838(86)90125-1 · DOI
  26. 10.1161/hyp.33.3.835 · DOI
  27. 10.1165/ajrcmb.13.2.7626287 · DOI
  28. 10.1016/0014-2999(88)90423-2 · DOI
  29. 10.1161/hyp.36.1.116-a · DOI
  30. 10.1161/res.81.3.372 · DOI
  31. Aoyagi T. Small molecular protease inhibitors and their biological effects.In: Kleinkauf H von Döhren H eds. Biochemistry of Peptide Antibiotics. Recent Advances in the Biotechnology of B-Lactams and Microbial Bioactive Peptides. Berlin: W. de Gruyter; 1990: 311–363. · DOI
  32. 10.1016/0024-3205(67)90090-2 · DOI
  33. Caughey GH. Chymase.In: Barrett AJ ed. Handbook of Proteolytic Enzymes London: Academic Press; 1998; 66–70.
  34. 10.1016/0006-291X(88)90257-4 · DOI · Paper page
  35. 10.1159/000157116 · DOI
  36. 10.1161/01.hyp.21.6.925 · DOI
  37. 10.1007/s000180050482 · DOI · Paper page
  38. 10.1073/pnas.79.15.4535 · DOI · Paper page
  39. 10.1016/0006-2952(95)00191-2 · DOI
  40. 10.1016/0006-2952(95)00074-A · DOI
  41. 10.1016/0006-2952(91)90106-F · DOI
  42. 10.1093/oxfordjournals.jbchem.a130461 · DOI
  43. 10.1172/JCI116325 · DOI
  44. 10.1161/01.hyp.19.6.692 · DOI
  45. 10.1161/circ.95.6.1455 · DOI
  46. Springman EB. Mast cell carboxypeptidase.In: Barrett AJ ed. Handbook of Proteolytic Enzymes. London: Academic Press; 1998: 1330–1333.
  47. 10.1016/S0021-9258(17)34557-X · DOI
  48. 10.1161/res.88.10.1072 · DOI
  49. 10.1016/S0165-6147(00)01644-8 · DOI

Cited by

Sorted by citations

See all 110

Metadata

Authors
Jackman, H. L., Massad, M. G., Sekosan, M., Tan, F., Brovkovych, V., Marcic, B. M., & Erdös, E. G.
Affiliations
From the Departments of Pharmacology (H.L.J., F.T., V.B., B.M.M., E.G.E.), Surgery (M.G.M.), Pathology (M.S.), and Anesthesiology (F.T., E.G.E.), University of Illinois College of Medicine at Chicago.
Venue
Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2002-05
Volume
39
Issue
5
Pages
976-981
ISSN
  • 0194-911X
  • 1524-4563
DOI
10.1161/01.hyp.0000017283.67962.02
Cited by
110
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiotensin 1–9 and 1–7 release in human heart role of cathepsin, A. https://app.cochat.ai/papers/10.1161/01.hyp.0000017283.67962.02
The paper
Jackman, H. L., Massad, M. G., Sekosan, M., Tan, F., Brovkovych, V., Marcic, B. M., & Erdös, E. G. (2002). Angiotensin 1–9 and 1–7 release in human heart role of cathepsin, A. Hypertension. https://doi.org/10.1161/01.hyp.0000017283.67962.02